| About: | Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, infectious disease, cardiovascular, coagulation, diabetes and renal injury, fertility, inflammation, thyroid hormone, rheumatoid arthritis, and others. It also provides blood coagulation, optical coagulation, and thrombelastography analyzer, as well as automatic chemiluminescence immunoassay and molecular diagnostic analyzers; blood gas analyzer; fully automated pathology staining system; and hemoglobin analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company sells its products to approximately 150 countries and regions worldwide. The company was founded in 1992 and is based in Guangzhou, China. |